David J. Schlanger Buys 150,000 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares of the company’s stock, valued at $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Progyny Price Performance

Shares of NASDAQ PGNY opened at $16.90 on Friday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 29.14, a price-to-earnings-growth ratio of 1.64 and a beta of 1.35. The business has a 50-day moving average of $15.23 and a two-hundred day moving average of $20.51. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $42.08.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period last year, the firm earned $0.16 earnings per share. As a group, equities research analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current year.

Institutional Trading of Progyny

A number of institutional investors have recently bought and sold shares of PGNY. Bank of New York Mellon Corp lifted its holdings in Progyny by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company’s stock worth $21,636,000 after buying an additional 22,012 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Progyny by 31.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,470 shares of the company’s stock valued at $643,000 after purchasing an additional 5,428 shares during the last quarter. F M Investments LLC purchased a new stake in shares of Progyny in the 2nd quarter valued at about $326,000. Crossmark Global Holdings Inc. lifted its holdings in shares of Progyny by 12.4% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 18,286 shares of the company’s stock valued at $523,000 after purchasing an additional 2,019 shares during the last quarter. Finally, nVerses Capital LLC lifted its holdings in shares of Progyny by 925.0% in the 2nd quarter. nVerses Capital LLC now owns 4,100 shares of the company’s stock valued at $117,000 after purchasing an additional 3,700 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PGNY. Truist Financial reaffirmed a “hold” rating and issued a $19.00 price objective (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $17.00 price objective (down from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Canaccord Genuity Group dropped their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Bank of America dropped their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Leerink Partners dropped their price objective on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research note on Thursday, September 19th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Hold” and a consensus target price of $25.00.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.